COMMUNIQUÉS West-GlobeNewswire

Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients

09/01/2025 - 14:30

Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A total of five patients have completed the 24-month study. Following the [...]

Hydreight Technologies Provides Shareholder Update on 2024 Milestones and 2025 Vision

09/01/2025 - 14:30

VANCOUVER, British Columbia and LAS VEGAS, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a rapidly growing mobile clinical network [...]

Biosphere Launches UV Bioreactor to Transform Industrial Fermentation

09/01/2025 - 14:30

Following $8.8m seed round, Biosphere aims to slash biomanufacturing’s capital costs by more than 50% OAKLAND, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Biosphere , a startup developing advanced bioproduction systems, [...]

Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships

09/01/2025 - 14:30

Company Making Additions to Executive Team and Advisory Board to Support Significant Commercial Momentum LONDON, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Oribiotech Ltd (Ori), a leader in cell and gene therapy (CGT) [...]

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

09/01/2025 - 14:05

-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune [...]

Amwell® divests virtual psychiatric care business to Avel eCare in all-cash transaction

09/01/2025 - 14:00

Divestment of Amwell Psychiatric Care intended to focus product portfolio on key growth initiatives Company reiterates guidance for 2024 BOSTON, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a global leader [...]

Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential

09/01/2025 - 14:00

FMC-220 is a first-in-class covalent activator of p53 Y220C designed to address potency and tolerability challenges of non-covalent approaches In preclinical studies, FMC-220 demonstrated unprecedented potency and [...]

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

09/01/2025 - 14:00

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing [...]

Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

09/01/2025 - 14:00

The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of innovation and growing [...]

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

09/01/2025 - 14:00

Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer’s disease (AD) Sabirnetug demonstrated selective [...]

New England Life Care Selects Inovalon’s ScriptMed® to Scale Infusion Therapy and Specialty Pharmacy

09/01/2025 - 14:00

ScriptMed Infusion will Accelerate New England Life Care's Patient-Centric Care and Scale Pharmacy Operations BOWIE, Md., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Inovalon , a leading provider of cloud-based software solutions [...]

Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics

09/01/2025 - 14:00

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced [...]

ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

09/01/2025 - 13:30

WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced that Chairman and [...]

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

08/01/2025 - 22:30

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 08 janv. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]

Monthly information on share capital and company voting rights

08/01/2025 - 22:30

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results

08/01/2025 - 22:30

AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year [...]

Lifeward Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

08/01/2025 - 22:15

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what [...]

Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

08/01/2025 - 22:15

-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of [...]

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

08/01/2025 - 22:14

PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced [...]